What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?

In the ADRIATIC study, stage I or II limited-stage SCLC comprised only about 12% of patients randomized. The point estimate of HR regarding survival benefit was 0.92, with a wide confidence interval exceeding 1.0 (upper range more than 2). I do not recommend durvalumab consolidation for those with s...